IP Library › Granted Patent US 8,835,467
Granted Patent B2
US 8,835,467 · App. 13/747,543 · Granted Sep 16, 2014

SIR2 regulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,835,467
App. No.
13/747,543
Granted
Sep 16, 2014
Kind
B2
Abstract

Compounds are disclosed which inhibit SIR2 base exchange more than deacetylation, thus enhancing SIR2 deacetylation activity. Methods of using the compounds for enhancing SIR2 deacetylation activity and increasing longevity of an organism are also disclosed. Methods for screening for compounds that enhance SIR2 deacetylation activity and increase longevity of an organism are additionally disclosed.

Claims (13)

1. A composition formulated for topical administration comprising isonicotinamide in an amount effective to increase protein deacetylation by a SIR2 enzyme in a living cell.

2. The composition of claim 1 , wherein the cell is an archaeal cell or a prokaryotic cell.

3. The composition of claim 1 , wherein the cell is part of a living organism.

4. The composition of claim 1 , wherein the cell is a human cell.

5. The composition of claim 3 , wherein the living organism is a mammal.

6. The composition of claim 3 , wherein the living organism is a human.

7. The composition of claim 1 , wherein the SIR2 enzyme is selected from the group consisting of SIR2A, SIRT3, SIRT2p, SIRT1p, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7.

8. The composition of claim 1 , wherein the composition includes one or more of propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone, ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate and polyvinyl pyrrolidone.

9. A composition formulated for topical administration comprising isonicotinamide in an amount effective to activate a SIR2 enzyme in a living cell.

10. The composition of claim 9 , wherein the cell is in a mammal.

11. The composition of claim 9 , wherein the cell is in a human.

12. The composition of claim 9 , wherein the SIR2 enzyme is selected from the group consisting of SIR2A, SIRT3, SIRT2p, SIRT1p, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6 and SIRT7.

13. The composition of claim 9 , wherein the composition includes one or more of propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, N-methylpyrrolidone, ethylcellulose, hydroxypropyl cellulose, ethylene/vinylacetate and polyvinyl pyrrolidone.

Assignments (5)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CORRECTIVE ASSIGNMENT TO CORRECT PATENT NO. 8726046 TO 8729046 PREVIOUSLY RECORDED AT REEL: 036876 FRAME: 0018. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 28, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036984/0184 →
CHANGE OF NAME Recorded Oct 20, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036907/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036876/0018 →
CONFIRMATORY LICENSE Recorded Jun 8, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035859/0034 →